—
C+
C+ The full Closelooknet — membership. Open the C+ overview

AbbVie Inc (ABBV) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for ABBV, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 62/100 · S&P 500 fund at 67, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-25
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +8.4% over 20 sessions. Factor regime → 2026-09-25
  • Sovereign pressure Index 0.61 · up 0.29 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-25
How it trades on rate days beta 0.26 to TLT · on the worst bond days it held up better than the market

How it trades on rate days

How ABBV has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.26 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), AbbVie Inc moved 0.26% on average · correlation 0.09 · higher than 25% of US names
  • Beta, last 3 months 0.41 about the same as over the year
  • On the 10 worst bond days −0.11% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +0.02% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Drug Manufacturers - General · US · 8 names with week and year-to-date

Peer group

Drug Manufacturers - General · US

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against ABBV on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — AbbVie Inc

ABBV in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
AbbVie is a biopharmaceutical company that researches, makes and sells medicines and treatments worldwide. Its range covers Skyrizi and Rinvoq for immune disease, Imbruvica and Venclexta for blood cancers, Elahere and Epkinly for other cancers, and Botox and Juvederm for aesthetic use. It also sells eye care, digestive and migraine products. The company is based in North Chicago, Illinois.
Where it sits in the stack
AbbVie carries no Rubin or Halo seat, so it sits outside the AI build-out layers the diary tracks. In our universe it belongs to the Healthcare sector, within the drug manufacturers industry group.
Who it is priced against
Closelooknet has not set a peer group for AbbVie. The market commonly compares it with other large pharmaceutical makers, Pfizer among them, on pipeline breadth and franchise mix.
Why Closelooknet tracks it
AbbVie holds a seat in the S&P 500 among our indices but carries no Rubin or Halo listing and no Closelooknet score yet. It has not appeared in the diary's quoted editions.
What the diary watches
The diary watches how AbbVie's newer immunology and oncology drugs perform against its older franchises, and whether analyst price targets keep moving away from the current level.

AbbVie Inc (ABBV) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: ABBV news on the tape · index compare · sector dispersion · scanner.

The Street on this name 1 analyst action on the wire · latest: price target by Piper Sandler, 2026-08-20

The Street on this name

Analyst actions and the latest print for ABBV from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Piper Sandler — target 303 from 298 Target raised to $303 from $298 (+13.9% to spot) 2026-08-20

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

Dividends and capital return trailing yield 2.58%, quarterly · last 1.73 USD on 2026-07-15

Dividends and capital return

What ABBV pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 6.83 USD per share · a 2.58% yield on the 2026-09-25 close 4 distributions, paid quarterly 2026-09-25
  • Change on the year +5.4% against the prior twelve months prior twelve months 6.48 USD per share
  • Last distribution 1.73 USD per share as the price series records it, within days of the ex-date 2026-07-15
  • By calendar year 2023: 1.48 USD (partial) · 2024: 6.21 USD · 2025: 6.56 USD · 2026: 5.19 USD to date first distribution recorded in the three-year window: 2023-10-12

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-09-26

Quick answers

What is AbbVie Inc (ABBV)?

AbbVie Inc trades as ABBV on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-09-26.

Is ABBV in a Closelooknet index?

Not currently — AbbVie Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-09-26.

Where does ABBV trade against its moving averages?

Uptrend stack intact: Trades +2.8% vs the 50-day and +15.2% vs the 200-day average, 1.9% below the 52-week high and +38.6% off the 52-week low; a golden cross printed 58 sessions ago. Computed from daily closes. As of 2026-09-25 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does AbbVie Inc trade when bond yields rise?

Over the past year AbbVie Inc had a beta of 0.26 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 25% of US names. On the 10 sessions in which long bonds fell most it moved −0.11% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does AbbVie Inc do?

AbbVie is a biopharmaceutical company that researches, makes and sells medicines and treatments worldwide. Its range covers Skyrizi and Rinvoq for immune disease, Imbruvica and Venclexta for blood cancers, Elahere and Epkinly for other cancers, and Botox and Juvederm for aesthetic use. It also sells eye care, digestive and migraine products. Closelooknet has not set a peer group for AbbVie. The market commonly compares it with other large pharmaceutical makers, Pfizer among them, on pipeline breadth and franchise mix.

Where does AbbVie Inc sit in the AI build-out?

AbbVie carries no Rubin or Halo seat, so it sits outside the AI build-out layers the diary tracks. In our universe it belongs to the Healthcare sector, within the drug manufacturers industry group. AbbVie holds a seat in the S&P 500 among our indices but carries no Rubin or Halo listing and no Closelooknet score yet. It has not appeared in the diary's quoted editions.

Does AbbVie Inc pay a dividend?

AbbVie Inc has paid 6.83 USD per share over the last twelve months, paid quarterly, a trailing yield of 2.58% on the 2026-09-25 close; the last distribution recorded in the price series was 1.73 USD on 2026-07-15. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on AbbVie Inc recently?

The most recent analyst action on AbbVie Inc on the Closelooknet wire is a price target by Piper Sandler on 2026-08-20 (target 303 from 298). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for ABBV, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.